参考文献/References:
[1] Cummings SR, San Martin J, McClung MR,et al. Denosumab for prevention of fractures in
postmenopausal women with osteoporosis[J].N Engl J Med,2009,361(8):756-765. DOI:
10.1056/NEJMoa0809493.
[2] Bone HG, Chapurlat R, Brandi ML,et al. The effect of three or six years of denosumab
exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension[J].J Clin
Endocrinol Metab,2013,98(11):4483-4492. DOI: 10.1210/jc.2013-1597.
[3] BologneseæMA, Teglbjærg CS, Zanchetta JR,et al. Denosumab significantly increases
DXA BMD at both trabecular and cortical sites: results from the FREEDOM study[J].J Clin
Densitom,2013,16(2):147-153. DOI: 10.1016/j.jocd.2012.02.006.
[4] Genant HK, Libanati C, Engelke K,et al. Improvements in hip trabecular, subcortical, and
cortical density and mass in postmenopausal women with osteoporosis treated with denosumab
[J].Bone,2013,56(2):482-488. DOI: 10.1016/j.bone.2013.07.011.
[5] Keaveny TM, McClung MR, Genant HK,et al. Femoral and vertebral strength improvements in
postmenopausal women with osteoporosis treated with denosumab[J].J Bone Miner Res,2014,29
(1):158-165. DOI: 10.1002/jbmr.2024.
[6] Brown JP, Reid IR, Wagman RB,et al. Effects of up to 5 years of denosumab treatment on bone
histology and histomorphometry: the FREEDOM study extension[J].J Bone Miner Res,2014,29(9):2051
-2056. DOI: 10.1002/jbmr.2236.
[7] McClung MR, Boonen S, Törring O,et al. Effect of denosumab treatment on the risk of
fractures in subgroups of women with postmenopausal osteoporosis[J].J Bone Miner Res,2012,27
(1):211-218. DOI: 10.1002/jbmr.536.
[8] Jamal SA, Ljunggren O, Stehman-Breen C,et al. Effects of denosumab on fracture and bone
mineral density by level of kidney function[J].J Bone Miner Res,2011,26(8):1829-1835. DOI:
10.1002/jbmr.403.
[9] Palacios S, Agodoa I, Bonnick S,et al. Treatment satisfaction in postmenopausal women
suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate
or ibandronate[J].J Clin Endocrinol Metab,2015,100(3):E487-E492. DOI: 10.1210/jc.2014-3594.
[10] Brown JP, Prince RL, Deal C,et al. Comparison of the effect of denosumab and alendronate on
BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a
randomized, blinded, phase 3 trial[J].J Bone Miner Res,2009,24(1):153-161. DOI:
10.1359/jbmr.080901.
[11] Zhang L, Pang Y, Shi Y,et al. Indirect comparison of teriparatide, denosumab, and oral
bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal
women with osteoporosis[J].Menopause,2015,22(9):1021-1025. DOI: 10.1097/GME.0000000000000466.
[12] Bone HG, Bolognese MA, Yuen CK,et al. Effects of denosumab treatment and discontinuation on
bone mineral density and bone turnover markers in postmenopausal women with low bone mass[J].J
Clin Endocrinol Metab,2011,96(4):972-980. DOI: 10.1210/jc.2010-1502.
[13] Brown JP, Roux C, T rring O,et al. Discontinuation of denosumab and associated fracture
incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6
Months(FREEDOM)trial[J].J Bone Miner Res,2013,28(4):746-752. DOI: 10.1002/jbmr.1808.
[14] Langdahl BL, Teglbjærg CS, Ho PR,et al. A 24-month study evaluating the efficacy and
safety of denosumab for the treatment of men with low bone mineral density: results from the
ADAMO trial[J].J Clin Endocrinol Metab,2015,100(4):1335-1342. DOI: 10.1210/jc.2014-4079.
[15] Ellis GK, Bone HG, Chlebowski R,et al. Randomized trial of denosumab in patients receiving
adjuvant aromatase inhibitors for nonmetastatic breast cancer[J].J Clin Oncol,2008,26(30):4875-
4882. DOI: 10.1200/JCO.2008.16.3832.
[16] Gnant M, Pfeiler G, Dubsky PC,et al. Adjuvant denosumab in breast cancer(ABCSG-18): a
multicentre, randomised, double-blind, placebo-controlled trial[J].Lancet,2015,386(9992):433-
443. DOI: 10.1016/S0140-6736(15)60995-3.
[17] Smith MR, Egerdie B, Hernández Toriz N,et al. Denosumab in men receiving androgen-
deprivation therapy for prostate cancer[J].N Engl J Med,2009,361(8):745-755. DOI:
10.1056/NEJMoa0809003.
[18] Stopeck AT, Lipton A, Body JJ,et al. Denosumab compared with zoledronic acid for the
treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind
study[J].J Clin Oncol,2010,28(35):5132-5139. DOI: 10.1200/JCO.2010.29.7101.
[19] Henry DH, Costa L, Goldwasser F,et al. Randomized, double-blind study of denosumab versus
zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding
breast and prostate cancer)or multiple myeloma[J].J Clin Oncol,2011,29(9):1125-1132. DOI:
10.1200/JCO.2010.31.3304.
[20] Denosumab for the prevention of skeletal complications in metastatic castration-resistant
prostate cancer: comparison of skeletal-related events and symptomatic skeletal events[J].Ann
Oncol,2015,26(6):1274. DOI: 10.1093/annonc/mdv155.
[21] Smith MR, Saad F, Coleman R,et al. Denosumab and bone-metastasis-free survival in men with
castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled
trial[J].Lancet,2012,379(9810):39-46. DOI: 10.1016/S0140-6736(11)61226-9.
[22] Hofbauer LC, Zeitz U, Schoppet M,et al. Prevention of glucocorticoid-induced bone loss in
mice by inhibition of RANKL[J].Arthritis Rheum,2009,60(5):1427-1437. DOI: 10.1002/art.24445.
[23] Polyzos SA, Singhellakis PN, Naot D,et al. Denosumab treatment for juvenile Paget's
disease: results from two adult patients with osteoprotegerin deficiency("Balkan" mutation in
the TNFRSF11B gene)[J].J Clin Endocrinol Metab,2014,99(3):703-707. DOI: 10.1210/jc.2013-3762.
[24] Grasemann C, Schündeln MM, Hövel M,et al. Effects of RANK-ligand antibody
(denosumab)treatment on bone turnover markers in a girl with juvenile Paget's disease[J].J Clin
Endocrinol Metab,2013,98(8):3121-3126. DOI: 10.1210/jc.2013-1143.
[25] Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone[J].J Bone Miner
Res,2006,21(Suppl 2):P114-P119.
[26] Piersanti S, Remoli C, Saggio I,et al. Transfer, analysis, and reversion of the fibrous
dysplasia cellular phenotype in human skeletal progenitors[J].J Bone Miner Res,2010,25(5):1103-
1116. DOI: 10.1359/jbmr.091036.
[27] Boyce AM, Chong WH, Yao J,et al. Denosumab treatment for fibrous dysplasia[J].J Bone Miner
Res,2012,27(7):1462-1470. DOI: 10.1002/jbmr.1603.
[28] Ganda K, Seibel MJ. Rapid biochemical response to denosumab in fibrous dysplasia of bone:
report of two cases[J].Osteoporos Int,2014,25(2):777-782. DOI: 10.1007/s00198-013-2585-1.
[29] Benhamou J, Gensburger D, Chapurlat R. Transient improvement of severe pain from fibrous
dysplasia of bone with denosumab treatment[J].Joint Bone Spine,2014,81(6):549-550. DOI:
10.1016/j.jbspin.2014.04.013.
[30] Becker J, Semler O, Gilissen C,et al. Exome sequencing identifies truncating mutations in
human SERPINF1 in autosomal-recessive osteogenesis imperfecta[J].Am J Hum Genet,2011,88(3):362-
371. DOI: 10.1016/j.ajhg.2011.01.015.
[31] Hoyer-Kuhn H, Netzer C, Koerber F,et al. Two years' experience with denosumab for children
with osteogenesis imperfecta type Ⅵ[J].Orphanet J Rare Dis,2014,9:145.DOI: 10.1186/s13023-014-
0145-1.